股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 領航醫藥生物科技有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00399 | 說明 | 領航醫藥生物科技 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,0 ...

Group 1 - The latest shareholder equity disclosures for three companies: Vanguard Medical Biotechnology (00399), Huaxin Cement (06655), and CSPC Pharmaceutical Group (01093) were made on September 3, 2025 [1] Group 2 - Vanguard Medical Biotechnology: - Shareholder Mao Yumin reduced holdings from 1.55 billion shares to 1.50 billion shares, holding percentage decreased from 72.33% to 70.00% [2] - Huaxin Cement: - Shareholder Li Yeqing increased holdings from 454,000 shares to 508,600 shares, holding percentage increased from 0.03% to 0.04% [2] - CSPC Pharmaceutical Group: - Shareholder Cai Xin increased holdings from 50,000 shares to 100,000 shares, holding percentage remained at 0% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 於二零二五年八月二十九日舉行之 股東週年大會之投票表決結果 茲提述領航醫藥及生物科技有限公司（「本公司」）於二零二五年七月三十一日 之通函（「該通函」）及股東週年大會通告（「該通告」）。除文義另有所指外，本公 告所用詞彙與該通函所界定者具有相同涵義。 股東週年大會之投票表決結果 董事會欣然宣佈，於二零二五年八月二十九日舉行之股東週年大會上，該通告 所載之所有提呈之決議案經股東根據上市規則第13.39(4)條以投票表決方式獲 正式通過。 於股東週年大會當日，合共有2,142,787,625股已發行股份，這是由有權出席股 東週年大會及於大會上表決所有提呈之決議案之股東所持有的股份總數。根 據上市規則，概無股東須於股東週年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 澄清公告 根據一般授權配售新股份 茲提述本公司日期為二零二五年八月二十一日的公告，內容有關（其中包括） 本公司與中國北方證券集團有限公司（作為配售代理）訂立日期為二零二五年 八月二十一日的配售協議，按每股配售股份0.415港元的配售價認購本公司最 多145,000,000股配售股份（「該公告」）。除另有指明者外，本公告所用詞彙與該 公告所界定者具有相同涵義。 – 1 – 除上文披露者外，該公告所載的所有其他資料及內容均維持不變。本澄清公告 為該公告的補充，並應於該公告一併閱讀。 承董事會命 領航醫藥及生物科技有限公司 主席 仰融 香港，二零二五年八月 ...

Core Viewpoint - The company has extended the deadline for the subscription agreement with Subscriber A from August 26, 2025, to September 16, 2025, or another date mutually agreed upon in writing by both parties [1] Group 1 - The company announced the need for additional time to fulfill the conditions precedent outlined in the subscription agreement [1] - A further extension letter has been signed with Subscriber A to formalize the new deadline [1]

領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 茲提述本公司日期為二零二五年七月十五日、二零二五年七月十六日及二零 二五年八月五日的公告（「該等公告」），內容有關張彪兵及陳靜按每股認購股 份0.3124港元的認購價分別認購本公司60,000,000股股份及30,000,000股股份。除 文義另有規定外，本公告所用詞彙與該等公告所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 進一步延長最後截止日期 除上文所述者外，認購協議B（經補充協議B及日期為二零二五年八月五日的延 長函件修訂及補充）的所有其他條款及條件將維持不變，且繼續全面有效及生效。 承董事會命 領航醫藥及生物科技有限公司 主席 仰融 認購協議A 根據認購協議A（經補充協議A及日期為二零二五年八月五日的延長函件修訂及 補充），倘先決條 ...

Group 1 - The core focus of the company is on the research and development of oral insulin products, as well as the trade of beauty instruments and products [1] - The company aims to acquire commercially viable pharmaceutical products [1] - The company was formerly known as United Gene Technology Group and is now listed on the Hong Kong Stock Exchange under stock code 399 [1] Group 2 - As of the 2024 annual report, the company reported total revenue of 1.9296 million and a net loss of 319 million [2]

Core Viewpoint - The company has announced a placement agreement with a placement agent to issue up to 145 million shares at a price of HKD 0.415 per share, representing a discount of approximately 9.78% from the closing price of HKD 0.46 on August 21, 2025 [1] Group 1 - The placement is aimed at attracting at least six independent third-party subscribers [1] - If fully subscribed, the 145 million shares will account for about 6.34% of the company's enlarged issued share capital [1] - The total expected proceeds from the placement are approximately HKD 60.175 million, with net proceeds estimated at around HKD 58.825 million after deducting related expenses [1]

Core Viewpoint - The company, Pioneer Pharmaceuticals Biotechnology (00399), has announced a placement agreement to issue up to 145 million shares at a price of HKD 0.415 per share, which represents a discount of approximately 9.78% from the closing price of HKD 0.46 on August 21, 2025 [1] Group 1 - The placement is expected to involve at least six independent third-party subscribers [1] - If all shares are fully placed, the total proceeds from the placement will be approximately HKD 60.175 million [1] - After deducting related expenses of about HKD 1.35 million, the estimated net proceeds will be around HKD 58.825 million [1] Group 2 - The net proceeds from the placement are intended to be used entirely for funding the company's blockchain technology business development [1]

Core Viewpoint - The company, Vanguard Pharmaceuticals (00399.HK), has entered into a placement agreement to issue up to 145 million shares at a price of HKD 0.415 per share, which represents a discount of approximately 9.78% from the closing price of HKD 0.460 on the date of the agreement [1] Group 1 - The placement is expected to involve at least six independent third-party subscribers [1] - The estimated net proceeds from the placement, after deducting related expenses of approximately HKD 1.35 million, are expected to be around HKD 58.825 million [1] - The company intends to use the net proceeds entirely for funding the development of its blockchain technology business [1]